Heat Biologics, Inc. Protocol HS410-101 HS410-101 SAP version 1.0 Page 1 of 25 HEAT BIOLOGICS, INC. STATISTICAL ANALYSIS PLAN FOR PROTOCOL HS410-101 A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients with Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT) Protocol number: HS410-101 Study phase: Phase 1/2 Product name: Vesigenurtacel-L (HS-410) Indication: Non-muscle invasive bladder cancer Investigators: Multicenter Date of protocol: Version 8.0 (Amendment 7.0), 03-Feb-2016 Version Date: 18-Oct-2016 Confidential Statement Information in this document is confidential and should not be disclosed, other than to those directly involved in the execution of the study, without written authorization from the sponsor. Heat Biologics, Inc. Protocol HS410-101 HS410-101 SAP version 1.0 Page 3 of 25 Table of Contents Approval Page ................................................................................................................................... 2 Table of Contents ...............................................................................................................................